NeoPharm Co

NeoPharm Co Inventory

The Inventory of NeoPharm Co (092730.KQ) as of Oct 28, 2026 is 15.58 B KRW. In the previous year, Inventory was 12.68 B KRW — a change of 22.89% (higher).

Inventory

15.58 BKRW

YoY

22.89%

Last updated:

Inventory of NeoPharm Co is 2025 15.58 B KRW. Inventory of NeoPharm Co was 2024 12.68 B KRW. It decreases by 22.89% higher compared to the previous year.

The NeoPharm Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
6.84 B KRW
Jan 1, 2019
5.84 B KRW
Jan 1, 2020
8.09 B KRW
Jan 1, 2021
7.97 B KRW
Jan 1, 2022
8.75 B KRW
Jan 1, 2023
10.20 B KRW
Jan 1, 2024
12.68 B KRW
Jan 1, 2025
15.58 B KRW
The NeoPharm Co Inventory history
YEARInventoryYoY
15.58 BKRW+22.89%
12.68 BKRW+24.33%
10.20 BKRW+16.53%
8.75 BKRW+9.73%
7.97 BKRW-1.44%
8.09 BKRW+38.51%
5.84 BKRW-14.67%
6.84 BKRW+41.30%
4.84 BKRW+16.53%
4.16 BKRW-2.09%
4.25 BKRW+49.11%
2.85 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoPharm Co Stock analysis

What does NeoPharm Co do? NeoPharm Co., Ltd. generates revenue through the development, manufacture, and sale of cosmetics, medical, and health products under its own brand names. The company sells ATOPALM products, which include daily care, intensive care, special care, and baby care items, as well as Derma:B products such as foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, BB creams, sun protectors, white watering serums, and anti-aging eye creams. ZEROID products, featuring creams and lotions for skin barrier recovery and hypoallergenic foaming cleansers for atopic and sensitive skin, also contribute to sales. Additionally, NeoPharm provides original equipment manufacturing (OEM) services for skin drugs, supplying these to other companies. The primary buyers of NeoPharm's products are consumers seeking skincare solutions for daily use, sensitive skin conditions, and medical-grade treatments. ATOPALM targets general skincare and baby care markets, while Derma:B appeals to users looking for comprehensive skincare routines including anti-aging and sun protection. ZEROID focuses on individuals with atopic or sensitive skin requiring gentle, hypoallergenic products. OEM services are purchased by other pharmaceutical companies needing skin drug manufacturing capabilities. NeoPharm's product portfolio is structured around four key brands: ATOPALM, Derma:B, ZEROID, and OEM services. ATOPALM and Derma:B cater to broad consumer segments in the cosmetics and skincare industry, with Derma:B offering a wide range of products for various skin concerns. ZEROID serves a specialized segment for sensitive skin care, and OEM services target business-to-business clients in the pharmaceutical sector. The company's revenue streams are thus diversified across consumer-facing brands and B2B manufacturing contracts. NeoPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NeoPharm Co stock

Inventory of NeoPharm Co is 15.58 B KRW in 2025.

Inventory of NeoPharm Co changed from 12.68 B KRW to 15.58 B KRW, representing a 22.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory NeoPharm Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's NeoPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NeoPharm Co

All Key Metrics — NeoPharm Co